Abliva AB (publ) (NEVPF) Stock Price, News & Analysis

Company Overview

Abliva AB (publ) is a Swedish biotechnology company focused on developing treatments for primary mitochondrial diseases, a group of rare genetic disorders caused by impaired mitochondrial function. The company’s work centers on therapies intended to address the energy deficiencies and debilitating symptoms associated with these conditions.

Abliva’s lead drug candidate is KL1333, an orally administered therapy being developed for adults with genetically confirmed primary mitochondrial disease. The company has also researched NV354, a potential treatment for mitochondrial diseases involving complex II deficiency, including Leigh syndrome. Its development programs have included clinical and preclinical research conducted in collaboration with international healthcare and research organizations.

The company was formerly known as NeuroVive Pharmaceutical AB and adopted the Abliva name in 2020. Based in Lund, Sweden, Abliva has pursued a global clinical-development strategy for rare diseases and has sought regulatory and commercial partnerships to advance its mitochondrial medicine programs.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.03
• 52-Week Range: $0.01 to $0.04
• Volume: N/A
• Average Volume: 4,445 shs
• Market Capitalization: $11.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:NEVPF
• CIK: N/A
• Web: www.neurovive.com
• Phone: (646) 275-6220
• Fax: 46-4-688-883-48
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -117.92%
• Return on Assets: -102.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.99
• Quick Ratio: 7.99

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,128.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 403,010,000
• Free Float: N/A
• Market Cap: $11.28 million
• Optionable: Not Optionable
• Beta: -1.18